JPWO2020229553A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020229553A5 JPWO2020229553A5 JP2021565875A JP2021565875A JPWO2020229553A5 JP WO2020229553 A5 JPWO2020229553 A5 JP WO2020229553A5 JP 2021565875 A JP2021565875 A JP 2021565875A JP 2021565875 A JP2021565875 A JP 2021565875A JP WO2020229553 A5 JPWO2020229553 A5 JP WO2020229553A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- seq
- amino acid
- protein
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025001728A JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906685.1A GB201906685D0 (en) | 2019-05-13 | 2019-05-13 | Activatable protein constructs and uses thereof |
| GB1906685.1 | 2019-05-13 | ||
| GBGB1910254.0A GB201910254D0 (en) | 2019-05-13 | 2019-07-17 | Activatable protein constructs and uses thereof |
| GB1910254.0 | 2019-07-17 | ||
| GBGB1917678.3A GB201917678D0 (en) | 2019-05-13 | 2019-12-04 | Activatable protein constructs and uses thereof |
| GB1917678.3 | 2019-12-04 | ||
| GBGB2001196.1A GB202001196D0 (en) | 2019-05-13 | 2020-01-28 | Activatable protein constructs and uses thereof |
| GB2001196.1 | 2020-01-28 | ||
| PCT/EP2020/063362 WO2020229553A1 (en) | 2019-05-13 | 2020-05-13 | Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001728A Division JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022532534A JP2022532534A (ja) | 2022-07-15 |
| JPWO2020229553A5 true JPWO2020229553A5 (https=) | 2023-05-22 |
| JP2022532534A5 JP2022532534A5 (https=) | 2023-05-22 |
| JP7617027B2 JP7617027B2 (ja) | 2025-01-17 |
Family
ID=67384589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565875A Active JP7617027B2 (ja) | 2019-05-13 | 2020-05-13 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
| JP2025001728A Pending JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001728A Pending JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230192899A1 (https=) |
| EP (1) | EP3969116A1 (https=) |
| JP (2) | JP7617027B2 (https=) |
| KR (1) | KR20220008841A (https=) |
| CN (2) | CN113840634B (https=) |
| AU (1) | AU2020276891A1 (https=) |
| BR (1) | BR112021022661A2 (https=) |
| CA (1) | CA3138827A1 (https=) |
| GB (4) | GB201906685D0 (https=) |
| IL (1) | IL287890A (https=) |
| MX (1) | MX2021013844A (https=) |
| SG (1) | SG11202112114YA (https=) |
| WO (1) | WO2020229553A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| EP4034171A1 (en) * | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| JP2023547499A (ja) * | 2020-11-06 | 2023-11-10 | ノバルティス アーゲー | 抗体Ｆｃ変異体 |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023144423A1 (en) * | 2022-01-31 | 2023-08-03 | LockBody Therapeutics Ltd | Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof |
| CA3246893A1 (en) * | 2022-03-30 | 2023-10-05 | Centessa Pharmaceuticals (Uk) Limited | Activable Bispecific Anti-CD3 and Anti-PD-L1 Proteins and Their Uses |
| WO2023192973A1 (en) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| CA3251998A1 (en) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Novel masked antibodies |
| GB202302074D0 (en) * | 2023-02-14 | 2023-03-29 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2024218512A1 (en) * | 2023-04-19 | 2024-10-24 | Centessa Pharmaceuticals (Uk) Limited | Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof |
| WO2024218509A1 (en) * | 2023-04-19 | 2024-10-24 | Centessa Pharmaceuticals (Uk) Limited | Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof |
| KR20250088543A (ko) * | 2023-05-19 | 2025-06-17 | 서울대학교산학협력단 | Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포 |
| CN121866269A (zh) * | 2023-09-14 | 2026-04-14 | Abl生物公司 | 通过施用抗pd-l1/抗4-1bb双特异性抗体治疗癌症的方法 |
| WO2026038050A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038047A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038048A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2352763T5 (pl) * | 2008-10-01 | 2023-01-30 | Amgen Research (Munich) Gmbh | Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej |
| CA2822366A1 (en) | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| AU2015323313B2 (en) * | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
| KR102499191B1 (ko) * | 2016-03-18 | 2023-02-13 | 프레드 허친슨 캔서 센터 | Cd20 면역요법을 위한 조성물 및 방법 |
| CR20180453A (es) * | 2016-03-22 | 2018-12-05 | Hoffmann La Roche | Moleculas biespecíficas de células t activadas por proteasas |
| AU2018250641B2 (en) * | 2017-04-11 | 2025-03-13 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
| EP3668897B1 (en) | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
-
2019
- 2019-05-13 GB GBGB1906685.1A patent/GB201906685D0/en not_active Ceased
- 2019-07-17 GB GBGB1910254.0A patent/GB201910254D0/en not_active Ceased
- 2019-12-04 GB GBGB1917678.3A patent/GB201917678D0/en not_active Ceased
-
2020
- 2020-01-28 GB GBGB2001196.1A patent/GB202001196D0/en not_active Ceased
- 2020-05-13 BR BR112021022661A patent/BR112021022661A2/pt unknown
- 2020-05-13 AU AU2020276891A patent/AU2020276891A1/en active Pending
- 2020-05-13 WO PCT/EP2020/063362 patent/WO2020229553A1/en not_active Ceased
- 2020-05-13 KR KR1020217038644A patent/KR20220008841A/ko active Pending
- 2020-05-13 EP EP20726749.3A patent/EP3969116A1/en active Pending
- 2020-05-13 CA CA3138827A patent/CA3138827A1/en active Pending
- 2020-05-13 CN CN202080034818.9A patent/CN113840634B/zh active Active
- 2020-05-13 SG SG11202112114YA patent/SG11202112114YA/en unknown
- 2020-05-13 US US17/610,899 patent/US20230192899A1/en active Pending
- 2020-05-13 MX MX2021013844A patent/MX2021013844A/es unknown
- 2020-05-13 CN CN202510701821.6A patent/CN120554533A/zh active Pending
- 2020-05-13 JP JP2021565875A patent/JP7617027B2/ja active Active
-
2021
- 2021-11-07 IL IL287890A patent/IL287890A/en unknown
-
2025
- 2025-01-06 JP JP2025001728A patent/JP2025039660A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020229553A5 (https=) | ||
| US12378323B2 (en) | IgM and IgE heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity | |
| US12378325B2 (en) | Multispecific antigens binding fragments and multspecific antibodies | |
| JP7846668B2 (ja) | リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質 | |
| US20220017640A1 (en) | Activatable bispecific antibodies | |
| Kontermann et al. | Bispecific antibodies | |
| CA2892623C (en) | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof | |
| HRP20241417T1 (hr) | Bifunkcionalno antitijelo anti-pd-1 i anti-vegfa, njegov farmaceutski pripravak i njegova uporaba | |
| US12098203B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2021515541A5 (https=) | ||
| JP2021516537A5 (https=) | ||
| CN115943161A (zh) | 结合mait和肿瘤细胞两者的多特异性抗体 | |
| CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
| JP2021515542A5 (https=) | ||
| WO2018237364A1 (en) | Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in caner therapy | |
| JPWO2019170898A5 (https=) | ||
| RU2021135215A (ru) | Активируемые белковые конструкции и их применение | |
| EP4688841A1 (en) | All-in-one agonistic antibodies | |
| JPWO2019170885A5 (https=) | ||
| JPWO2019175186A5 (https=) | ||
| WO2025162454A1 (zh) | 双特异性抗体和细胞因子融合蛋白及其应用 | |
| WO2025162453A1 (zh) | 双特异性抗体前药及其应用 | |
| HK40058120A (en) | Multispecific mutated antibody fab fragments | |
| HK40103459A (en) | Multispecific mutated antibody fab fragments |